Replies to post #798786 on NorthWest Biotherapeutics Inc (NWBO)

[AllSheWrote]

Is it possible that the MHRA has given NWBO whatever time is necessary to qualify the EDEN and new cleanrooms for commercial use before approving everything.

No.

[DrHigh]

There is absolutely no reason to not obtain approval w/ manual manufacturing, raise capital at reasonable terms to inject steroids into multiple trials/projects INCLUDING Eden.

Not buying any of this nonsense

[meirluc]

"If this were the case, essentially, we're on hold until the EDEN's ready to go"

If this were the case, it would greatly delay MHRA's Approval and wouldn't that
qualify as "material information" that should be PR'd. So where is that PR?

[meirluc]

"Northwest Biotherapeutics (NWBO) has not publicly announced a request to the MHRA for a CMC expansion to include the Flaskworks/Eden system as part of its initial Marketing Authorization Application (MAA). The company has maintained a policy of not commenting on the specifics of the ongoing MHRA review process.
The MAA for DCVax-L was submitted on December 21, 2023, and the company has not disclosed receiving any formal letters of concern (RFI) from the MHRA. The MAA review has exceeded the MHRA's standard 150-business day target, but this delay is widely considered to be a result of general administrative backlogs within the MHRA and is not unique to NWBO's application.
Potential Impact of a CMC Expansion
If NWBO were to request a substantial change or expansion to the Chemistry, Manufacturing, and Controls (CMC) section of its MAA during the review process, especially to include a new manufacturing technology like Flaskworks/Eden, it would likely elicit a substantial delay.
Regulatory Scrutiny: The MHRA would need to thoroughly review and validate the new manufacturing process and facility, which is a complex and time-consuming undertaking that is generally handled as a post-approval variation or a separate, later submission.
Shareholder Communication: As a publicly traded company, any material event, including a significant delay in a key regulatory approval process due to an unexpected change in the application, would typically need to be communicated to shareholders via official channels like SEC filings or press releases to ensure transparency and compliance with reporting requirements.
Current Status
NWBO's strategy appears to involve getting the initial approval based on the existing manufacturing process, and then submitting a variation to add the more efficient Flaskworks system for commercial-scale production later. The company has announced the successful acquisition of its manufacturing arm, Advent BioServices, and is preparing its facilities for the post-approval commercialization phase, which includes the eventual integration of Flaskworks.
In summary, there is no public information to suggest that NWBO has requested an MAA expansion for Flaskworks, nor has it attributed the current MAA timeline to such a request. The general delay is likely due to the MHRA's workload, a situation the company has not specifically commented on beyond general risk factors mentioned in SEC filings."
..